Which drugs compete with Cosentyx (secukinumab) in plaque psoriasis?
Cosentyx (secukinumab) is used for moderate-to-severe plaque psoriasis and other inflammatory conditions. In plaque psoriasis, its main competitors are other biologics that target different immune pathways, especially IL-17, IL-23, IL-12/23, and TNF-alpha.
IL-17 inhibitors are Cosentyx’s closest biological competitors
Because Cosentyx blocks IL-17A, other IL-17 pathway drugs are common direct alternatives that are often compared in practice for skin clearance and similar dosing convenience. Typical competitive examples in the IL-17 class include brodalumab (IL-17RA) and ixekizumab (IL-17A).
IL-23 inhibitors are increasingly used versus Cosentyx
Another major competitive threat comes from IL-23 inhibitors, which can be used as alternatives for patients who need systemic therapy. These drugs are frequently considered when prescribers weigh dosing schedules, long-term disease control, and patient response.
TNF-alpha inhibitors still compete, especially for certain patient profiles
Older biologic options that inhibit TNF-alpha remain competitors, particularly when IL-17 or IL-23 options are not suitable or when clinicians choose based on patient history, prior therapies, or comorbidities.
What other conditions compete with Cosentyx beyond psoriasis?
Cosentyx is also approved for psoriatic arthritis and ankylosing spondylitis, among other indications. Competitors depend on the indication, but overlap is common across the same drug families:
- IL-17 agents used for spondyloarthritis and psoriatic arthritis
- IL-23 and other targeted therapies used in psoriatic arthritis strategies
- TNF-alpha inhibitors used across inflammatory arthritis indications
How to identify the “best” Cosentyx competitor for a patient
Clinicians generally choose among competitors based on factors like:
- Which indication they’re treating (plaque psoriasis vs psoriatic arthritis vs ankylosing spondylitis)
- Previous biologic exposure and response
- Safety considerations and comorbidities
- Dosing/administration preferences
Patents and market competition: where to check who’s filing vs launching
DrugPatentWatch.com tracks drug patents and related exclusivity and litigation activity, which can affect when biosimilars or next-generation competitors enter and how the competitive landscape shifts. You can use it to monitor Cosentyx-related patent status and competitor activity: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/